Title: A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate at Week 52 of Secukinumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Active Psoriatic Arthritis (Phase IIIb clinical trial).
- PI: MARÍA DOLORES LOPEZ MONTILLA
- Protocol: CAIN457F2366
- Sponsor: NOVARTIS FARMACEUTICA, S.A.
- Date: 30/01/2017- 31/01/2020
Title: Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects with a History of Anterior Uveitis (C-View) (Phase IV clinical trial).
- PI: EDUARDO COLLANTES ESTÉVEZ
- Protocol: AS0007
- Sponsor: UCB BIOPHARMA SPRL
- Date: 09/02/2017- 31/01/2020
Title: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) (Phase III clinical trial).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: M14-465
- Sponsor: ABBVIE DEUTCHSLAND GMBH & CON K. G
- Date: 09/02/2017- 30/06/2022
Title: A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis (Phase II clinical trial).
- PI: EDUARDO COLLANTES ESTEVEZ
- Protocol: AS0008
- Sponsor: UCB BIOPHARMA SPRL
- Date: 14/02/2017-31/01/2020
Title: A Multicenter, Randomized, Double-Blind study compared to placebo, for 24 weeks, following by a long-term treatment evaluating the Eficacy and Safety of Baricitinib in active psoriatic arthritis patients (Phase III clinical trial).
- PI: MARÍA DOLORES LÓPEZ MONTILLA
- Protocol: I4V-MC-JAHA
- Sponsor: LILLY, S.A.
- Date: 09/05/2017-31/03/2021
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic (Phase III Clinical Trial)
- PI: MARÍA DOLORES LÓPEZ MONTILLA
- Protocol: CNTO1959PSA3002
- Sponsor: JANSSEN-CILAG INTERNATIONAL N.V.
- Date: 22/05/2017-31/12/2022
Title: A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis (Phase IV Clinical Trial)
- PI: EDUARDO COLLANTES ESTÉVEZ
- Protocol: MK-8259-038
- Sponsor: MERCK SHARP & DOHME DE ESPAÑA SA
- Date: 23/05/2017-28/02/2022
Title: A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab to Evaluate the Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Non-radiographic Axial Spondyloarthritis (Phase III clinical trial)
- PI: MARÍA DEL CASTRO VILLEGAS
- Protocol: CAIN457H2315
- Sponsor: NOVARTIS FARMACEUTICA, S.A.
- Date: 29/05/2017-30/06/2020
Title: A Phase 4 Open-label Randomized Controlled Study Comparing the Effectiveness of Adalimumab introduction and Methotrexate Dose escalation in Subjects With Psoriatic Arthritis (CONTROL) (Phase IV clinical Trial)
- PI: MARÍA DOLORES LÓPEZ MONTILLA
- Protocol: M14-496
- Sponsor: ABBVIE DEUTCHSLAND GMBH & CON K. G
- Date: 02/06/2017-30/11/2018
Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active RA (Phase I/III Clinical trial)
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: CT-P13-3.5
- Sponsor: CELLTRION INC
- Date: 03/07/2017-31/07/2019
Title: Cross-sectional observational study to evaluate adherence to treatment RA patients in Spain (Independent Post-authorization Study).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: FRD-ART-2017-01
- Sponsor: FUNDACION RAMÓN DOMÍNGUEZ (IDICHUS)
- Date: 05/07/2017-05/08/2018
Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate The Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-alpha Inhibitors (Phase II clinical trial).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: BP39261
- Sponsor: LA ROCHE LTD
- Date: 23/08/2017-31/05/2019
Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Apremilast (CC-10004) in the treatment of active ankylosing spondylitis (Phase III clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: CC-10004-AS-001
- Sponsor: Celgene International SARL
- Date: 16/08/2012-31/07/2018
Title: Evaluation of the clinical utility of a standarized dose-reduction protocol in patients with axial spodiloarthritis (AS) in persistent clinical remission with TNF antagonist treatment: Randomized, controlled, multicenter, open-label study (Phase IV clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: REDES-TNF-2012
- Sponsor: SOCIEDAD ESPAÑOLA DE FARMACOLOGIA CLÍNICA
- Date: 30/07/2012-30/07-2015
Title: Immunogenicity of anti-TNF therapies in patients with rheumatic diseases. (Clinical studies).
- PI: María del Carmen Castro Villegas
- Protocol: PFI-ANT-2012-01
- Sponsor: PFIZER, S.L.U.
- Date: 25/09/2012- 31/12/2014
Title: Beneficial effects of coenzyme Q10 treatment on the mitocondrial dysfunction and oxidative stress associated to atherothrombosis development in antiphospholipid syndrome patients (Coenzyme Q10) (Independent clinical trial).
- PI: Rosario López Pedrera
- Protocol: PI12-01511
- Sponsor: Maimónides Biomedical Research Institute of Córdoba.
- Date: 29/05/2013- 30/06/2015
Title: Prevalence of axial and peripheral spondyloarthritis in first-degree relatives of ankylosing spondylitis patients (Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: SCI-SPAI-2011-01
- Sponsor: ABBOTT LABORATORIES, S.A.
- Date: 07/02/2012- 31/05/2013
Title: SCORE: Monitoring and control in rheumatology-nursing (Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: SCORE
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 10/04/2012- 10/04/2014
Title: Evaluation of pain in Rheumatology (Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: SER-ANA-2012-01
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 20/08/2012- 20/03/2013
Title: National registry of SLE from SER (Clinical study).
- PI: Mª Angeles Aguirre Zamorano
- Protocol: SER-LES-2010-01
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 15/02/2012- 15/02/2013
Title: A randomized, controlled study of Sarilumab and Metotrexate (MTX) versus etanercept and MTX in patients with rheumatoid arthritis (RA) and an inadequate response to 4 months of treatment with adalimumab and MTX. (Phase III clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: EFC11574
- Sponsor: SANOFI AVENTIS RECHERCHE & DEVELOPPEMENT
- Date: 26/09/2013- 31/12/2016
Title: Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone (Phase II clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: GLPG0634-CL-203
- Sponsor: GALAPAGOS NV
- Date: 23/07/2013- 01/02/2015
Title: A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab (Phase IV clinical trial).
- PI: Mª Angeles Aguirre Zamorano
- Protocol: HGS1006-C1113
- Sponsor: HUMAN GENOME SCIENCES
- Date: 06/03/2013- 06/11/2022
Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis (Phase III clinical trial).
- PI: Mª Dolores López Montilla
- Protocol: I1F-MC-RHAP
- Sponsor: ELI LILLY AND COMPANY
- Date: 18/10/2013- 01/02/2017
Title: Spanish registry of axial spondyloarthritis patients treated with anti-TNF (Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: JMG-TNF-2011-01
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 29/08/2013- 31/12/2017
Title: Phase IIIb study to evaluate the efficacy, safety and tolerability of subcutaneous tocilizumab administered in monotherapy or combined with methotrexate (MTX) and other non-biological DMARDs in patients with rheumatoid arthritis (Phase III clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: ML27809
- Sponsor: ROCHE FARMA, S.A.
- Date: 11/10/2013- 28/12/2016
Title: Preferences of rheumatologists and patients for biological agent attributes used in the treatment of rheumatic diseases in Spain (Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: MSD-BIO-2012-01
- Sponsor: MERCK SHARP & DOHME DE ESPAÑA SA
- Date: 02/04/2013- 02/07/2013
Title: Retrospective study of patients with rheumatoic diseases who started treatment with biological therapies (ESE-BIO study) (Clinical study).
- PI: María del Carmen Castro Villegas
- Protocol: MSD-REU-2013-01
- Sponsor: MERCK SHARP & DOHME DE ESPAÑA SA
- Date: 27/06/2013- 01/06/2014
Title: A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (Phase I clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: 1293.2
- Sponsor: BOEHRINGER INGELHEIM ESPAÑA, S.A.
- Date: 12/02/2013-30/04/2016
Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as) (Phase II clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: A3921119
- Sponsor: PFIZER INC
- Date: 14/06/2013-31/10/2014
Title: Observational cross-sectional study on the functional and work-related limitation of daily life in patients with systemic sclerosis who present o not with digital ulcers (Clinical study).
- PI: Alejandro Escudero Contreras
- Protocol: ACT-NUL-2012-01
- Sponsor: ACTELION PHARMACEUTICALS ESPAÑA, S.L.
- Date: 18/01/2013-18/04/2013
Title: A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis (Phase III clinical trial).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: ML28709
- Sponsor: ROCHE FARMA, S.A.
- Date: 11/10/2013- 28/12/2016
Title: A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis (Phase III Clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: CAIN457F2314
- Sponsor: NOVARTIS FARMACEUTICA, S.A.
- Date: 29/10/2013-01/10/2017
Title: Patients with axial spondyloarthritis: Multi-Country Registry of clinical characteristics, including radiographic progression, and burden of disease over 5 years in real-life setting) (Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: 10297
- Sponsor: ABBVIE SPAIN S.L.U.
- Date: 13/02/2014- 31/12/2019
Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-1 (Phase III clinical trial).
- PI: Mª Dolores López Montilla
- Protocol: 20090406
- Sponsor: AMGEN INC.
- Date: 19/02/2014- 01/10/2018
Title: Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy (Phase IV clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: FER-TOC-2013-01
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 24/03/2014- 31/12/2015
Title: A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis (Phase II clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: GLPG0634-CL-205
- Sponsor: GALAPAGOS NV
- Date: 17/02/2014- 01/02/2019
Title: A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis (Phase III clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: M13-375
- Sponsor: ABBVIE SPAIN S.L.U.
- Date: 07/04/2014- 31/05/2017
Title: Study on therapeutic compliance in rheumatoid arthritis patients in threatment with subcutaneous administration of biological drugs. ARCO study (Clinical study).
- PI: Alejandro Escudero Contreras
- Protocol: MSD-ART-2013-01
- Sponsor: MERCK SHARP & DOHME DE ESPAÑA SA
- Date: 26/05/2014- 31/01/2016
Title: A Retrospective, Multicentre Observational Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Real Life in Patients With Rheumatoid Arthritis (Clinical Study).
- PI: Jerusalén Calvo Gutiérrez
- Protocol: SAR-FAM-2013-01
- Sponsor: FUNDACION ANDALUZA DE REUMATOLOGIA
- Date: 09/01/2014- 31/12/2014
Title: GEMA 2 project: Gout: Evaluation and management (Clinical study).
- PI: Alejandro Escudero Contreras
- Protocol: SER-GOT-2014-01
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 02/09/2014- 31/03/2015
Title: Evaluation and accreditation of health care quality in the clinical managment of rheumatoid arthritis in response to Tream to Target (T2T) strategy (Independent clinical study).
- PI: Alejandro Escudero Contreras
- Protocol: ARexcellence
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 26/11/2014-31/12/2015
Title: A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate (Phase II clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: ALX0061-C202
- Sponsor: ABLYNX N.V.
- Date: 21/04/2015- 31/08/2018
Title: A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX 0061 (Phase II clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: ALX0061-C203
- Sponsor: ABLYNX N.V.
- Date: 14/07/2015-31/08/2018
Title: A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06410293 And Adalimumab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate (Phase III clinical trial).
- PI: Alejandro Escudero Contreras
- Protocol: B5381002
- Sponsor: PFIZER, S.L.U.
- Date: 15/06/2015-28/02/2018
Title: ASCORE study on long-term experience with subcutaneous abatacept in usual clinical practice (Clinical study).
- PI: Alejandro Escudero Contreras
- Protocol: BMS-ABA-2014-01
- Sponsor: BRISTOL-MYERS SQUIBB EMEA SARL (FR)
- Date: 19/02/2015-28/02/2019
Title: A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis (Phase III clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: CAIN457F2320
- Sponsor: NOVARTIS FARMACEUTICA, S.A.
- Date: 20/04/2015-30/04/2018
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis (Phase III clinical trial).
- PI: Mª Dolores López Montilla.
- Protocol: CNTO148PSA3001
- Sponsor: JANSSEN BIOLOGICS B.V.
- Date: 20/01/2015-31/01/2020
Title: Spanish registry of psoriatic arthritis (Clinical study).
- PI: Mª Dolores López Montilla
- Protocol: REAPSER
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 20/01/2015-31/12/2021
Title: Validation of the EARP questionnaire for the detection of psoriatic artritis in Spanish population. VALS study (Clinical Study).
- PI: Mª Dolores López Montilla
- Protocol: SCI-SPAI-2013-02
- Sponsor: ABBVIE SPAIN S.L.U.
- Date: 20/01/2015-31/12/2016
Title: Non-interventional study to evaluate the efficaty of certolizumab PEGOL in axial spondyloarthritis patients in the daily practice. (Independent Clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: UCB-CER-2015-01
- Sponsor: UCB BIOPHARMA SPRL
- Date: 20/05/2015-31/12/2017
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis. (Phase III clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: CNTO1275AKS3002
- Sponsor: JANSSEN-CILAG, S.A.
- Date: 06/07/2015-31/12/2019
Title: Spanish registry of adverse events of biology and biosimilar therapies in rheumatic diseases. (Phase III clinical study).
- PI: Eduardo Collantes Estévez
- Protocol: FER-ADA-2015-01
- Sponsor: FUNDACION ESPAÑOLA DE REUMATOLOGIA
- Date: 09/07/2015- 09/07/2019
Title: Clinical applicability of a standardized dose-reduction protocol in patients in persistent clinical revision, diagnosed with rheumatoid arthritis (RA), and treated with TNF antagonists (Clinical study).
- PI: Pilar Font Ugalde
- Protocol: FIB-ETA-2015-01
- Sponsor: FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
- Date: 26/10/2015- 31/10/2018
Title: A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis (Phase III clinical trial).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: GP15-301
- Sponsor: PHARMACEUTICAL PRODUCT DEVELOPMENT SPAIN S.L.
- Date: 15/09/2015- 30/06/2016
Title: Randomized, Double-blind, controlled, multicenter study of etanercept and metotrexate in combination or monotherapy in psoriatic arthritis subjects (Phase III clinical trial).
- PI: Mª Dolores López Montilla
- Protocol: 20130207
- Sponsor: AMGEN INC.
- Date: 01/12/2015- 30/09/2018
Title: A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5) (Phase III clinical trial).
- PI: Mª Dolores López Montilla
- Protocol: CAIN457F2342
- Sponsor: NOVARTIS FARMACEUTICA, S.A.
- Date: 16/09/2015-31/07/2019
Title: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee (Phase III clinical trial).
- PI: Miguel Angel Caracuel Ruíz
- Protocol: 42160443PAI3007
- Sponsor: JANSSEN-CILAG INTERNATIONAL N.V.
- Date: 13/07/2015-28/02/2017
Title: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and safety of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome (Phase II clinical trial).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: SS0004
- Sponsor: UCB BIOSCIENCES GMBH
- Date: 15/12/2015- 07/03/2017
Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee (Phase III clinical trial).
- PI: Miguel Angel Caracuel Ruíz
- Protocol: A4091057
- Sponsor: PFIZER INC
- Date: 10/05/2016- 31/03/2018
Title: A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement.
- PI: Miguel Angel Caracuel Ruíz
- Protocol: A4091064
- Sponsor: PFIZER INC
- Date: 01/07/2016- 30/09/2018
Title: A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo (Phase III clinical trial).
- PI: Eduardo Collantes Estévez
- Protocol: AS0005
- Sponsor: UCB BIOSCIENCES GMBH
- Date: 14/06/2016- 30/09/2019
Title: MAXIMISE (Managing Axial Manifestations in Psoriatic Arthritis With Secukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52 Week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Patients With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non Steroidal Anti-inflammatory Drugs (NSAIDs).
- PI: Mª Dolores López Montilla
- Protocol: CAIN457F3302
- Sponsor: NOVARTIS FARMACEUTICA, S.A.
- Date: 13/09/2016-31/12/2017
Title: An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Rheumatoid Arthritis (Clinical study).
- PI: Alejandro Escudero Contreras
- Protocol: CEL-INF-2016-01 (CT-P13 4.2)
- Sponsor: CELLTRION
- Date: 01/06/2016-01/06/2021
Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis (Phase III Clinical trial)
- PI: Eduardo Collantes Estévez
- Protocol: I1F-MC-RHBW
- Sponsor: LILLY, S.A.
- Date: 25/04/2016- 31/05/2018
Title: Observational study of UCOTRACK reproducibility, an automated determination of motion, in axial spondyloarthritis (Clinical study
- PI: Eduardo Collantes Estévez
- Protocol: MSD-ESP-2015-01
- Sponsor: MERCK SHARP & DOHME DE ESPAÑA SA
- Date: 07/07/2016- 07/01/2017
Title: A Comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis (Phase III clinical trial).
- PI: ALEJANDRO ESCUDERO CONTRERAS
- Protocol: YLB113-002
- Sponsor: YL BIOLOGICS LTD
- Date: 12/01/2016- 30/06/2017